It is therefore not surprising that strategies to counteract the detrimental action of estrogens on the proliferation of breast cancer cells have mainly focused on blocking the estrogen receptor (antiestrogens) and subsequently on blocking the formation of E2 (inhibitors of aromatase, STS, and certain 17β-HSDs). This evidence concerns the gene CYP19A1 and breast cancer.